Fig. 6From: Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational seriesThe hepatic metastatic pointed with arrow. Notes: a recurrence before chemotherapy. b partial response after chemotherapy/pretreatment of Olaparib. c progressive disease after using Olaparib. d partial response after chemotherapyBack to article page